r1507 + bevacizumab + docetaxel

This is a **combination therapy consisting of R1507, bevacizumab, and docetaxel**. - **R1507** is a recombinant, fully human monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), developed primarily as a cancer therapeutic to inhibit pathways involved in tumor growth and survival. Its mechanism is IGF-1R antagonism by preventing ligand binding and downstream signaling. - **Bevacizumab** is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGFA), thus blocking angiogenesis (formation of new blood vessels) required for tumor growth. - **Docetaxel** is a chemotherapeutic agent of the taxane class that binds to and stabilizes microtubules, thereby inhibiting cell division and promoting apoptosis in cancer cells. This combination aims to simultaneously inhibit tumor angiogenesis, growth signaling, and cell proliferation—potentially providing synergistic antitumor efficacy. While bevacizumab and docetaxel combinations are investigated and sometimes approved for metastatic breast cancer, prostate cancer, and non-small cell lung cancer, the specific combination including R1507 has primarily appeared in early-stage research for various solid tumors, particularly sarcomas and IGF-1R-dependent cancers.

Other names

r1507 + bevacizumab + docetaxel